Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NGFR-transduced autologous T lymphocytes

A preparation of autologous, genetically modified T lymphocytes that are expressing the tumor-associated antigen (TAA) nerve growth factor receptor (NGFR; p75 neurotrophin receptor; p75(NTR); CD271), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the NGFR-transduced autologous T lymphocytes may induce an immune response and may kill NGF-expressing tumor cells. Dysregulated NGF signaling may promote proliferation and invasion in certain tumor cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

NGFR-transduced autologous T lymphocytes

Search NCI's Drug Dictionary